# Capricor Therapeutics

其主打产品Deramiocel（原名CAP-1002）是一种同种异体心球来源细胞疗法，其对杜氏肌营养不良症的益处被认为部分通过旁分泌外泌体机制发挥作用，该公司的生物制品许可申请现已安排于2026年7月29日接受FDA咨询委员会审议，支撑数据包括HOPE-2开放标签扩展研究的五年数据及III期HOPE-3试验结果。

Source: https://cn.bioecon.ru/companies/capricor-therapeutics/
Updated: 2026-08-15

- 国家: United States
- 代码: CAPR

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 截至2026年3月31日现金、现金等价物及有价证券$278.6 million | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf |
| 产能 | 验证后满负荷运行预计可达到每年约2,000-2,500名患者或每年10,000剂的规模 | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf |
| 认证 | 圣地亚哥符合 GMP 标准的生产设施成功通过 FDA 发证前检查 | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf, https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310xex99d1.htm |
| 监管批准 | Deramiocel已获孤儿药、RMAT、ATMP及罕见儿科疾病资格认定；BLA正在FDA审查中，PDUFA日期为2026年8月22日 | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf, https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310xex99d1.htm |
| 生产基地 | 位于加州圣地亚哥的 GMP 生产设施 | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.biospace.com/press-releases/capricor-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf |
| 员工人数 | 截至2026年年中约有247至299名员工 [中等置信度] | https://altindex.com/ticker/capr/employees-linkedin, https://finance.yahoo.com/quote/CAPR/profile/ |
| 营收 | 2026年第一季度及2025年全年收入均为$0 | https://www.biospace.com/press-releases/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update, https://www.capricor.com/investors/sec-filings/all-sec-filings/content/0001104659-26-027037/0001104659-26-027037.pdf |

独立来源: altindex.com, biospace.com, finance.yahoo.com, sec.gov

## 技术

- [外泌体疗法与细胞外囊泡](https://cn.bioecon.ru/technology/exosome-therapy-extracellular-vesicles/)